newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort